{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+alafenamide+fumarate+%28TAF%29&page=3",
    "query": {
      "intervention": "tenofovir alafenamide fumarate (TAF)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 66,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+alafenamide+fumarate+%28TAF%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+alafenamide+fumarate+%28TAF%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T22:40:20.677Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02345226",
      "title": "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/RPV/TAF",
          "type": "DRUG"
        },
        {
          "name": "EFV/FTC/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "EFV/FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "FTC/RPV/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 881,
      "start_date": "2015-01-26",
      "completion_date": "2019-01-02",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 79,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345226"
    },
    {
      "nct_id": "NCT03547908",
      "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1/HBV Co-Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match DTG",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match F/TDF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 244,
      "start_date": "2018-05-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 4,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Berkley",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547908"
    },
    {
      "nct_id": "NCT01940471",
      "title": "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HBeAg-positive Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 875,
      "start_date": "2013-09-11",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01940471"
    },
    {
      "nct_id": "NCT04636437",
      "title": "Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Doravirine 100 Mg",
          "type": "DRUG"
        },
        {
          "name": "Integrase strand transfer inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide/emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir disproxil fumarate/emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2021-07-27",
      "completion_date": "2024-10-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04636437"
    },
    {
      "nct_id": "NCT04302896",
      "title": "Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Medication Adherence",
        "HIV"
      ],
      "interventions": [
        {
          "name": "dolutegravir oral tablet 50mg",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg",
          "type": "DRUG"
        },
        {
          "name": "tenofovir disoproxil fumarate oral tablet 300mg",
          "type": "DRUG"
        },
        {
          "name": "lamivudine oral tablet 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhonda Brand",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302896"
    },
    {
      "nct_id": "NCT05584397",
      "title": "Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV-1-infection",
        "HIV Disease Progression",
        "Inflammation",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Venipuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Targeted physical medical exam",
          "type": "PROCEDURE"
        },
        {
          "name": "Urine pregnancy test",
          "type": "PROCEDURE"
        },
        {
          "name": "Anoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Esophagogastroduodenoscopy (EGD)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-09-01",
      "completion_date": "2026-08-28",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05584397"
    },
    {
      "nct_id": "NCT01705574",
      "title": "Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "E/C/F/TDF",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "ATV Placebo",
          "type": "DRUG"
        },
        {
          "name": "RTV Placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 583,
      "start_date": "2012-10-24",
      "completion_date": "2018-09-06",
      "has_results": true,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 41,
      "location_summary": "Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01705574"
    },
    {
      "nct_id": "NCT01854775",
      "title": "Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Immune Deficiency Syndrome (AIDS)",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TAF (Low Dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2013-05-06",
      "completion_date": "2025-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 5,
      "location_summary": "Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854775"
    },
    {
      "nct_id": "NCT02707601",
      "title": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection",
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "F/R/TAF",
          "type": "DRUG"
        },
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2016-04-01",
      "completion_date": "2017-09-29",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02707601"
    },
    {
      "nct_id": "NCT02431247",
      "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunodeficiency Virus Type 1, Human"
      ],
      "interventions": [
        {
          "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC",
          "type": "DRUG"
        },
        {
          "name": "DRV/COBI FDC",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF FDC",
          "type": "DRUG"
        },
        {
          "name": "D/C/F/TAF FDC - Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF FDC Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "DRV/COBI FDC Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 725,
      "start_date": "2015-07-06",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-13T22:40:20.677Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431247"
    }
  ]
}